ADMA Biologics Inc (ADMA)

Pretax margin

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Earnings before tax but after interest (EBT)	US$ in thousands	-28,239	-65,904	-71,648	-75,749	-48,279
Revenue	US$ in thousands	258,215	154,080	80,943	42,220	29,349
Pretax margin		-10.94%	-42.77%	-88.52%	-179.41%	-164.50%

December 31, 2023 calculation

Pretax margin = EBT ÷ Revenue
= $-28,239K ÷ $258,215K
= -10.94%

The pretax margin of ADMA Biologics Inc has shown a positive trend over the past five years, improving from -164.50% in 2019 to -10.94% in 2023. This indicates that the company's ability to generate profits before taxes has strengthened over time. However, the pretax margin remains negative, suggesting that the company's operating expenses continue to outpace its revenues. It is essential for ADMA Biologics Inc to further enhance its operational efficiency and revenue generation efforts to achieve profitability and sustainable growth in the future.